AI Summary
✦ ClarthaValuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
50.16
Current
21.95
Overvalued
61.86
Undervalued
35.93
5Y Average
0.39
Current
0.36
Overvalued
0.45
Undervalued
0.33
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.4x Undervalued | -24% vs avg | +10.7% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 23.8x Undervalued | -46% vs avg | +17.1% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.5x Fair | +13% vs avg | +0.3% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.5x Premium | +107% vs avg | +123.1% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.3x Undervalued | -17% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.6x Fair | -12% vs avg | -15.4% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 40.0x Fair | -9% vs avg | +22.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Fair | -12% vs avg | +30.0% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.00 CrMar 2026Latest net profit
₹-68 CrMar 2026Latest EPS
₹-3.50Mar 2026Net margin
-4436.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 389 | 394 | 398 | 452 | 441 | 359 | 6 | 455 | 0 | 5 | 6 | 0 | 1 |
| Expenses + | 369 | 359 | 371 | 410 | 393 | 319 | 6 | 410 | 0 | 6 | 6 | 2 | 59 |
| Operating Profit | 20 | 36 | 27 | 42 | 49 | 40 | -1 | 45 | -0 | -1 | -0 | -2 | -57 |
| OPM % | 5% | 9% | 7% | 9% | 11% | 11% | -10% | 10% | -500% | -16% | -6% | -4,436% | |
| Other Income + | 18 | 0 | 11 | 0 | 1 | 1 | 7 | 1 | -130 | -62 | -176 | 35 | -24 |
| Interest | 20 | 18 | 21 | 25 | 24 | 20 | 0 | 17 | 0 | 0 | 0 | 30 | 6 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 15 | 0 | 16 | 0 | 1 | 0 | 0 | 0 |
| Profit before tax | 3 | 3 | 2 | 2 | 11 | 5 | 5 | 13 | -130 | -64 | -176 | 3 | -88 |
| Tax % | -68% | 41% | 38% | 36% | 95% | 40% | -2% | 38% | -0% | -1% | -0% | -339% | -22% |
| Net Profit + | 5 | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 |
| EPS in Rs | 0.24 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Sale And Surrender Of Leasehold Rights In Land Situated In Jammu
Announcement under Regulation 30 (LODR)-Change in Registered Office Address